ArticleMolecular informatics2026
A Multistep Computational Approach to Achieve a Complete Human 5-Lipoxygenase Structure and Provide a Pharmacophore Model for Further Drug Design.
Article in Molecular informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Human 5-lipoxygenase (5-LOX) plays a crucial role in the biosynthesis of leukotrienes (LTs). Therefore, 5-LOX inhibitors are designed as effective agents for the treatment of several diseases such as asthma, cardiovascular disorders, allergies, and cancer. Insights into crystal structures of several 5-LOX isoforms have revealed that this protein adopts two different conformations (open/closed) through modulation of its Hα2 and arched helix regions, which are conditioned by the presence or absence of ligand in the active site; moreover, these structures are incomplete in regions critical for ligand binding. To advance the design of 5-LOX inhibitors, we developed a computational procedure to reconstruct the first full-length open conformation structure of 5-LOX complexed with chelating inhibitor within the active site. Dynamic simulations and protein model validation confirmed the quality of our model, which was subsequently used for docking analyses and culminated in the development of a structure-based pharmacophore model. These computational studies might constitute powerful tools for rationally designing and identifying novel 5-LOX iron chelator inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.